HYL.BR WACC - Weighted Average Cost of Capital
The WACC of Hyloris Pharmaceuticals SA (HYL.BR) is 5.9%.
| Range | Selected | |
| Cost of equity | 5.1% - 6.7% | 5.9% |
| Tax rate | 0.0% - 0.0% | 0% |
| Cost of debt | 5.0% - 5.0% | 5% |
| WACC | 5.1% - 6.7% | 5.9% |
| Category | Low | High |
| Long-term bond rate | 2.9% | 3.4% |
| Equity market risk premium | 6.0% | 7.0% |
| Adjusted beta | 0.37 | 0.4 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 5.1% | 6.7% |
| Tax rate | 0.0% | 0.0% |
| Debt/Equity ratio | 0.01 | 0.01 |
| Cost of debt | 5.0% | 5.0% |
| After-tax WACC | 5.1% | 6.7% |
| Selected WACC | 5.9% | |
| Debt/Equity | Unlevered | |||
| Peers | Company Name | ratio | Beta | beta |
| HYL.BR | Hyloris Pharmaceuticals SA | 0.01 | 1.62 | 1.6 |
| ACPH.BR | Acacia Pharma Group PLC | 0.31 | 1.67 | 1.27 |
| AMYT.L | Amryt Pharma Holdings Ltd | 0.34 | 0.05 | 0.04 |
| ENZY.ST | Enzymatica AB (publ) | 0 | 0.69 | 0.69 |
| FCM.MI | Friulchem SpA | 2.72 | 0.15 | 0.04 |
| INDEX.ST | InDex Pharmaceuticals Holding AB | 0.01 | -0.92 | -0.91 |
| IRLAB A.ST | IRLAB Therapeutics AB | 0.18 | 0.13 | 0.11 |
| MARI.VI | Marinomed Biotech AG | 0.64 | 0.13 | 0.08 |
| PHO.OL | Photocure ASA | 0.02 | 0.11 | 0.11 |
| SHE.MI | Shedir Pharma Srl Unipersonale | 0.15 | -0.16 | -0.13 |
| Low | High | |
| Unlevered beta | 0.06 | 0.11 |
| Relevered beta | 0.06 | 0.1 |
| Adjusted relevered beta | 0.37 | 0.4 |
HYL.BR's CAPM model and how its cost of Equity is calculated
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for HYL.BR:
cost_of_equity (5.90%) = risk_free_rate (3.15%) + equity_risk_premium (6.50%) * adjusted_beta (0.37) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.